RDS has raised €14 million in Series A funding to accelerate the commercialization and industrialization of its MultiSense® remote patient monitoring device across Europe and prepare for entry into the U.S. market by 2028.

Target Information

RDS, a French medical technology company, has developed MultiSense®, a Class IIa remote monitoring device that provides healthcare professionals with a comprehensive, high-precision solution to continuously monitor several key physiological parameters of patients, either in hospitals or at home. This clinically validated technology is already being deployed across approximately 15 hospitals in France, Belgium, and Germany. Moreover, it has recently been referenced by major hospital purchasing groups such as RESAH and UNIHA.

With the new funding, RDS aims to significantly accelerate its development throughout France, Germany, and Europe. The company has plans to create several hundred jobs by 2035, particularly enhancing its sales team to meet the growing demand for the MultiSense solution. The funds will also be used to support the industrialization of the device, which is produced in France, with a goal of gradually increasing production and refurbishment capabilities.

Industry Overview

The global market for vital signs monitoring is expected to reach $15 billion by 2025, with a projected annual growth rate of 15% through 2030. This growth reflects a significant shift towards managing patients at home, both in France and internationally, driven by the intent